BlueStar
The new clearance expands its insulin dosing support to bolus and premixed insulin titration for Type 2 diabetes.
The pair will work on integrating Welldoc's software into Lilly's not yet released insulin pen.
Healthcare providers use a web interface to prescribe an initial dose "and BlueStar does the rest," according to Welldoc's chief medical officer.
Also: Consumer survey suggests declining digital health engagement; Iran's COVID-19 app pulled from Play Store after malware accusations.
Astellas will be paying Welldoc $15 million up front for certain rights to the diabetes digital therapeutic, and will also be on the hook for milestones and royalty payments.
This is the seventh FDA clearance for the longstanding mobile diabetes management platform.